
SkinScreener is a certified Class IIa medical device app that uses artificial intelligence to provide fast, easy, and accurate skin cancer risk assessment from photos of skin lesions. Developed in collaboration with the Medical University of Graz, the app offers a 95% accuracy in detecting malignant skin changes, making early detection accessible to everyone. It targets both individual users and companies for employee health protection, offering a comprehensive UV protection package alongside the app. SkinScreener's business model includes app sales and partnerships with companies and insurers to promote skin cancer prevention. The company is led by a team of medical and technical experts and has established partnerships with major Austrian companies and insurers, demonstrating traction with over 700,000 skin cancer risks detected and 250,000+ app downloads. The app supports regular self-monitoring and aims to reduce costly treatments by early detection, positioning itself as a leading digital health tool in skin cancer prevention.

SkinScreener is a certified Class IIa medical device app that uses artificial intelligence to provide fast, easy, and accurate skin cancer risk assessment from photos of skin lesions. Developed in collaboration with the Medical University of Graz, the app offers a 95% accuracy in detecting malignant skin changes, making early detection accessible to everyone. It targets both individual users and companies for employee health protection, offering a comprehensive UV protection package alongside the app. SkinScreener's business model includes app sales and partnerships with companies and insurers to promote skin cancer prevention. The company is led by a team of medical and technical experts and has established partnerships with major Austrian companies and insurers, demonstrating traction with over 700,000 skin cancer risks detected and 250,000+ app downloads. The app supports regular self-monitoring and aims to reduce costly treatments by early detection, positioning itself as a leading digital health tool in skin cancer prevention.
Product: AI-powered mobile app (Class IIa medical device) for skin lesion risk assessment
Clinical validation: Company cites a clinical study reporting ~95% accuracy
Traction: 250,000+ app downloads and 700,000 skin cancer risks detected (reported)
Headquarters: Graz, Styria, Austria (medaia GmbH)
Funding: Reported Angel-stage funding; total funding ~$270,000 (USD) reported
Early detection and monitoring of skin cancer via consumer and occupational health channels.
Digital health / Medtech
270000.00
Last funding date reported; public profiles obfuscate investor details